Elan, Isis Pharmaceuticals deal

ISIS and ELN terminated their HepaSense JV and amended their Orasense oral antisense JV. The Hepasense JV was developing ISIS’s ISIS 14803 antisense therapeutic against hepatitis C virus (HCV). As ter...